Skip to main content
. 2021 Feb 15;7(1):00170-2020. doi: 10.1183/23120541.00170-2020

TABLE 2.

Pharmacological and non-pharmacological treatment for patients with relapsing polychondritis

Patient Sex Age years CPAP Stent IS drugs Corticosteroid dose Previous drugs Baseline RPDAI
1 M 65 N N MTX Pred 37
2 F 70 N N MMF, infliximab Pred 5 mg SSZ 27
3 F 50 DNT N MTX Pred 45
4 F 53 Y Y MMF, MTX Pred 10 mg AZA, cyclophosphamide, ADA and ETN 47
5 F 76 Y N SSZ, HCQ, ABT, IVIG Pred 7.5 mg MTX, ETN, leflunomide, AZA 44
6 F 74 Y Y MTX, AZA Pred 10 mg Cyclophosphamide 43
7 F 76 Y N Cyclophosphamide Pred 10 mg MTX 27
8 F 70 N N AZA Pred 5 mg 15
9 F 78 DNT N Pred 5 mg MTX, AZA, HCQ 24
10 M 31 N N HCT 20/10/10 33
11 F 52 N N Secukinumab Pred 10 mg MTX, ETN, HCQ, cyclophosphamide, ADA 38
12 M 79 N N Pred 5 mg 35
13 M 78 Y Y MTX Pred 5 mg AZA 40

CPAP: continuous positive airway pressure; IS: immunosuppressant; RPDAI: Relapsing Polychondritis Activity Index; MTX: methotrexate; Pred: prednisolone; MMF: mycophenolate mofetil; SSZ: sulfasalazine; DNT: did not tolerate; AZA: azathioprine; ETN: etanercept; HCQ: hydroxychloroquine; ABT: abatacept; IVIG: intravenous immunoglobulin; HCT: hydrocortisone; ADA: adalimumab.